therapeutics

Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology.HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025…

2 days ago

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

December 09, 2025 21:42 ET  | Source: Dyne Therapeutics, Inc. WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.…

3 days ago

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed…

4 days ago

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm…

5 days ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

5 days ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

5 days ago

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today…

1 week ago

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

November 28, 2025 20:13 ET  | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina…

2 weeks ago

Menarini Group Announces New Data on ELZONRIS (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)BPDCN…

3 weeks ago

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0), a…

3 weeks ago
Show more Posts